American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
- PMID: 33290128
- PMCID: PMC12451922
- DOI: 10.1200/JCO.20.02953
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Abstract
This report presents the American Society of Clinical Oncology's (ASCO's) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and presents recommendations for moving forward as the pandemic recedes. ASCO organized its recommendations for clinical research around five goals to ensure lessons learned from the COVID-19 experience are used to craft a more equitable, accessible, and efficient clinical research system that protects patient safety, ensures scientific integrity, and maintains data quality. The specific goals are: (1) ensure that clinical research is accessible, affordable, and equitable; (2) design more pragmatic and efficient clinical trials; (3) minimize administrative and regulatory burdens on research sites; (4) recruit, retain, and support a well-trained clinical research workforce; and (5) promote appropriate oversight and review of clinical trial conduct and results. Similarly, ASCO also organized its recommendations regarding cancer care delivery around five goals: (1) promote and protect equitable access to high-quality cancer care; (2) support safe delivery of high-quality cancer care; (3) advance policies to ensure oncology providers have sufficient resources to provide high-quality patient care; (4) recognize and address threats to clinician, provider, and patient well-being; and (5) improve patient access to high-quality cancer care via telemedicine. ASCO will work at all levels to advance the recommendations made in this report.
Conflict of interest statement
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Disclosures provided by the authors are available with this article at DOI
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I 5 Immediate Family Member, Inst 5 My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Nathan A. Pennell
Melissa Dillmon
Ajjai S. Alva
Sibel Blau
Timothy L. Cannon
Natalie R. Dickson
Maximilian Diehn
Tari King
Stacie C. Lindsey
Jonathan Marron
Barbara L. McAneny
Kathryn Finch Mileham
Grzegorz S. Nowakowski
Manali I. Patel
Debra A. Patt
Gladys Rodriguez
Barry Russo
Cardinale B. Smith
Eleonora Teplinsky
Tiffany A. Traina
Robin Zon
Richard L. Schilsky
Howard A. Burris
No other potential conflicts of interest were reported.
References
-
- Waterhouse DM, Harvey RD, Hurley P, et al. : Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: Findings from an American Society of Clinical Oncology Survey. JCO Oncol Pract 16:417–421, 2020 - PubMed
-
- Moskowitz CS, Panageas KS: Implications for design and analyses of oncology clinical trials during the COVID-19 pandemic. JAMA Oncol 6:1326–1327, 2020 - PubMed
-
- Fleming TR, Labriola D, Wittes J: Conducting clinical research during the COVID-19 pandemic: Protecting scientific integrity. JAMA 324:33–34, 2020 - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical